| Ticker | Company | Sector | Entry Date | Entry Price | Current Price | P&L % |
|---|---|---|---|---|---|---|
| DELL | Dell Technologies Inc. | Technology | 2026-02-27 | $148.08 | $535.25 | +261.46% |
| CORT | Corcept Therapeutics Incorporated | Healthcare | 2026-03-30 | $38.12 | $115.70 | +203.52% |
| SNOW | Snowflake, Inc. | Technology | 2026-05-13 | $152.37 | $331.48 | +117.55% |
| MRNA | Moderna, Inc. | Healthcare | 2026-08-14 | $63.32 | $135.61 | +114.17% |
| PANW | Palo Alto Networks Inc. | Technology | 2026-04-09 | $166.99 | $335.10 | +100.67% |
Dell Technologies leads all FUM-tracked stocks with a +261.46% gain since its UP signal triggered February 27, 2026. Entering at $148.08, DELL has advanced to $535.25 as of the September 9 session, delivering $387.17 in profit per share across 134 trading sessions in the current UP trend.
The rally reflects Dell’s dominant positioning in AI infrastructure — specifically its PowerEdge server line engineered for enterprise AI workloads and large language model training environments. Surging demand from hyperscalers and corporate customers building GPU-dense compute environments has translated into earnings beats that repeatedly exceeded analyst expectations. With margins expanding as the product mix shifts toward higher-value AI-optimized configurations, the fundamental case has remained intact through the full six-month advance.
Corcept Therapeutics has posted a +203.52% gain since the UP signal triggered March 30, 2026, entering at $38.12 and advancing to $115.70 — a gain of $77.58 per share across 113 sessions in the current UP trend.
The company’s cortisol modulation platform — anchored by Korlym for endogenous Cushing’s syndrome — has broadened into solid tumor oncology through a late-stage pipeline that attracted sustained institutional accumulation across 2026. Positive data readouts for relacorilant and an expanding addressable market have re-rated Corcept from a single-product specialty name into a pipeline biotech, sustaining the advance well past its initial breakout. A clean balance sheet and improving earnings visibility have supported the run through multiple sector rotation cycles.
Snowflake has gained +117.55% since the UP signal on May 13, 2026, advancing from $152.37 to $331.48 — $179.11 per share — across 82 sessions in the current UP trend.
Accelerating enterprise adoption of the Data Cloud platform has been the structural driver, as companies consolidate analytics and AI workloads onto a single governed environment. Improving net revenue retention and expanding large customer counts reversed the deceleration narrative that had weighed on the stock through 2025. An expanded AI Data Cloud product line and deepened hyperscaler partnerships re-established Snowflake as critical infrastructure in the enterprise AI stack.
Moderna has surged +114.17% in 18 trading sessions since the UP signal triggered August 14, 2026, entering at $63.32 and reaching $135.61 — a gain of $72.29 per share and one of the sharpest short-duration advances in the FUM-tracked universe.
Positive late-stage clinical data for Moderna’s next-generation mRNA programs — including its respiratory combination vaccine candidate — triggered institutional rotation back into the platform. The stock had been deeply discounted relative to pipeline value following years of post-pandemic revenue normalization, and the catalyst sequence set off a sharp revaluation from a multi-year low base. Progress on the personalized cancer vaccine program co-developed with Merck reinforced conviction as the move extended.
Palo Alto Networks has gained +100.67% since the UP signal triggered April 9, 2026, entering at $166.99 and reaching $335.10 as of September 9 — $168.11 per share across 106 sessions in the current UP trend.
The platformization strategy has reached an inflection point as enterprise security budgets consolidate toward integrated platforms. Palo Alto has emerged as the primary beneficiary of that shift, with next-generation security annual recurring revenue growing sharply as CISOs rationalize vendor counts and redirect spending toward a unified offering. The structural move away from point-product proliferation continues to compound the company’s competitive advantage.
Three of the five top performers — Dell Technologies, Snowflake, and Palo Alto Networks — are Technology names, reflecting the convergence of AI infrastructure demand and enterprise security consolidation as the dominant themes driving outsized returns in 2026. Two Healthcare names, Corcept Therapeutics and Moderna, round out the group, underscoring that the strongest individual-stock moves span sectors when catalysts and trend alignment coincide.